A liquid injected into the heart that sets like a gel could one day prevent strokes caused by atrial fibrillation, animal tests suggest.
The U.S. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’ therapy for a rare form of obesity caused ...
The DIRECT ANGIO randomised clinical trial by Benjamin Gory and colleagues1 in The Lancet Neurology was designed to test a biologically compelling premise: that a direct transfer to angiography suite ...
Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being ...
XCath, a medical device company advancing neuro-endovascular surgical robotics, announced today the successful completion of ...
XCath today announced the completion of the first telerobotic stroke case using its Iris surgical robotic system.
Endovascular robot developer XCath said it has successfully completed its first remotely operated stroke procedure, linking a neurosurgeon with a patient more than a hundred miles away.
BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.
In 2023, the burden of stroke accounted for approximately 157 million disability-adjusted life years (DALYs), ranking second among all non-communicable diseases globally. Although age-standardised ...
New AAN guidance examines how consumer wearable devices can support neurologic care, including epilepsy monitoring and sleep tracking — while cautioning that many of them are insufficiently validated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results